Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
- Conditions
- Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
- Registration Number
- NCT00168740
- Lead Sponsor
- Biogen
- Brief Summary
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
- Diagnosis of relapsed, low-grade or follicular B-cell lymphoma
- CD20-positive lymphoma
- Progressive, measurable disease
- Sign informed consent
- 3 weeks beyond standard therapy
- Good performance status
- Adequate hematologic, renal, and hepatic function
- Chronic lymphocytic leukemia
- Lesions greater than or equal to 10 cm in diameter
- CNS lymphoma
- AIDS-related lymphoma
- Pleural effusions or ascites secondary to lymphoma
- Active, opportunistic infection
- Serious nonmalignant disease
- Prior investigational therapies, including prior anti-CD20 therapy
- Recent major surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method overall response rate
- Secondary Outcome Measures
Name Time Method time to disease progression progressive disease-free interval
Trial Locations
- Locations (31)
Hoag Hospital
πΊπΈNewport Beach, California, United States
Fox Chase Cancer Center
πΊπΈPhiladelphia, Pennsylvania, United States
Robert H. Lurie Cancer Center, Northwestern University
πΊπΈChicago, Illinois, United States
M.D. Anderson Cancer Center
πΊπΈHouston, Texas, United States
University of Arkansas for Medical Sciences
πΊπΈLittle Rock, Arkansas, United States
UCSD Stem Cell Laboratory
πΊπΈLa Jolla, California, United States
City of Hope Natioal Medical Center
πΊπΈDuarte, California, United States
Roswell Park Cancer Center
πΊπΈBuffalo, New York, United States
Kaiser Permanente Medical Center
πΊπΈVallejo, California, United States
Stanford University Medical Center
πΊπΈStanford, California, United States
Louisiana State University
πΊπΈShreveport, Louisiana, United States
University of Rochester Cancer Center
πΊπΈRochester, New York, United States
The West Clinic, P.C.
πΊπΈMemphis, Tennessee, United States
Michigan State University
πΊπΈEast Lansing, Michigan, United States
Georgetown University Medical Center
πΊπΈWashington, District of Columbia, United States
St. Louis University Medical Center
πΊπΈSt. Louis, Missouri, United States
University of Maryland Cancer Center
πΊπΈBaltimore, Maryland, United States
Toronto-Sunnybrook Regional Cancer Center
π¨π¦Toronto, Ontario, Canada
Sidney Kimmel Cancer Center
πΊπΈSan Diego, California, United States
University of Texas Health Sciences Center
πΊπΈSan Antonio, Texas, United States
University of California, San Francisco
πΊπΈSan Francisco, California, United States
University of Virginia
πΊπΈCharlottesville, Virginia, United States
University of Iowa General Hospital
πΊπΈIowa City, Iowa, United States
Sutter Cancer Center
πΊπΈSacramento, California, United States
Scripps Memorial Hospital
πΊπΈLa Jolla, California, United States
Rocky Mountain Cancer Center
πΊπΈDenver, Colorado, United States
Texas Oncology, P.A.
πΊπΈDallas, Texas, United States
Fred Hutchinson Cancer Research Center
πΊπΈSeattle, Washington, United States
University of Kentucky Medical Center
πΊπΈLexington, Kentucky, United States
University of Pittsburgh Medical Center
πΊπΈPittsburgh, Pennsylvania, United States
Ottawa General Hospital
π¨π¦Ottawa, Ontario, Canada